AMLX250117P25000
- 21.00
- 0.000.00%
Amylyx Pharmaceuticals Newsroom
Amylyx Pharmaceuticals Says FDA Lifts Clinical Hold on Phase 1 ALS Study
Amylyx Pharmaceuticals Announces FDA Lifts Clinical Hold On AMX0114 Phase 1 Clinical Trial In Treatment Of Amyotrophic Lateral Sclerosis
Express News | Amylyx Pharmaceuticals Inc - Anticipates Early Cohort Data From Lumina in 2025
Express News | Amylyx Pharmaceuticals Inc - to Move Forward With Trial Sites Across North America
Express News | Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on Amx0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals: Funds for Commercialization and Pipeline Programs, Working Capital, General Corporate Purposes >AMLX
Amylyx Pharmaceuticals: Commenced Underwritten Public Offering of Shares of Its Common Stock >AMLX
Amylyx Pharmaceuticals: All of Shares Being Offered by Amylyx >AMLX
Express News | Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
Insider Sale: Co-Chief Executive Officer of $AMLX (AMLX) Sells 7,471 Shares
Express News | Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now?
Amylyx and Gubra Join Forces for Peptide Drug Discovery Collaboration
Investors Don't See Light At End Of Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Tunnel And Push Stock Down 26%
Selling Amylyx Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
BofA Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $10
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $12
Express News | HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $12 Price Target
Express News | Amylyx Pharmaceuticals Shares up 1.7% on Late-Stage Trial Update for Low-Blood Sugar Drug